Inhibition of ERK1/2 activity by the MEK1/2 inhibitor AZD6244 (ARRY-142886) induces human multiple myeloma cell apoptosis in the bone marrow microenvironment: A new therapeutic strategy for MM.

被引：2
|
作者：
Tai, Yu-Tzu [1 ]
Li, Xian-Feng [1 ]
Breitkreutz, Iris [1 ]
Song, Weihua [1 ]
Burger, Peter [1 ]
Rumizen, Matthew [1 ]
Hideshima, Teru [1 ]
Podar, Klaus [1 ]
Ghobrial, Irene [1 ]
Schlossman, Robert [1 ]
Richardson, Paul [1 ]
Munshi, Nikhil C. [1 ]
Anderson, Kenneth C. [1 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
10.1182/blood.V108.11.3460.3460
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3460
引用
收藏
页码：987A / 987A
页数：1
相关论文
共 36 条
  • [31] A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study
    Coleman, Robert L.
    Sill, Michael W.
    Thaker, Premal H.
    Bender, David P.
    Street, Daron
    McGuire, William P.
    Johnston, Carolyn M.
    Rotmensch, Jacob
    GYNECOLOGIC ONCOLOGY, 2015, 138 (01) : 30 - 35
  • [32] Molecular Characterization and Clinical Correlations of MEK1/2 Inhibition (AZD6244) in Relapse or Refractory Multiple Myeloma: Analysis From a Phase II Study
    Zingone, Adriana
    Korde, Neha
    Chen, Jinqiu
    Xi, Liqiang
    Raffeld, Mark
    Holkova, Beata
    Kmieciak, Maciej
    Sullivan, Daniel
    Doyle, Austin
    Maric, Irina
    Calvo, Katherine
    Yancey, Mary Ann
    Mulquin, Marcia
    Annunziata, Christina
    Grant, Steven
    Landgren, Ola
    BLOOD, 2011, 118 (21) : 143 - 143
  • [33] A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens
    Bennouna, Jaafar
    Lang, Istvan
    Valladares-Ayerbes, Manuel
    Boer, Katalin
    Adenis, Antoine
    Escudero, Pilar
    Kim, Tae-You
    Pover, Gillian M.
    Morris, Clive D.
    Douillard, Jean-Yves
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (05) : 1021 - 1028
  • [34] A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens
    Jaafar Bennouna
    Istvan Lang
    Manuel Valladares-Ayerbes
    Katalin Boer
    Antoine Adenis
    Pilar Escudero
    Tae-You Kim
    Gillian M. Pover
    Clive D. Morris
    Jean-Yves Douillard
    Investigational New Drugs, 2011, 29 : 1021 - 1028
  • [35] The Mitogen-activated Protein Kinase (MAPK)/Extracellular Signal-regulated Kinase (ERK) 1/2 Kinase Inhibitor, AZD6244 (ARRY-142886) Enhances Radiosensitivity by Interfering with Radiation-induced TGF-alpha Signaling
    Chung, E.
    Urick, M.
    Kurshan, N.
    Shield, W.
    Riley, H.
    Citrin, D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : S564 - S564
  • [36] HIV-1 protease inhibitor induces growth arrest and apoptosis of human multiple myeloma cells via inactivation of STAT 3 and ERK1/2.
    Saito, T
    Ikezoe, T
    Yang, Y
    Koeffler, HP
    Taguchi, H
    BLOOD, 2003, 102 (11) : 372B - 372B
1234